Amy Barnett, D.O.
Faculty Associate

Dr. Amy Barnett is originally from Arizona and received her undergraduate degree in Physiology at the University of Arizona. She then continued her studies at the University of Arizona and completed a Master’s degree of Physiological Sciences. Throughout her undergraduate and graduate years, she was involved in research dedicated to studying the efficacy of novel cancer therapeutic agents. She completed her medical education at Midwestern University in Glendale, Arizona.   Dr. Barnett’s interests outside of medicine include family, art and music.

Other Post Graduate Training

University of Arizona (2010)

Graduate School

University of Arizona (2010)

Medical School

Arizona College of Osteopathic Medicine at Midwestern University (2015)

Residency

Scott & White Memorial Hospital (2018), Internal Medicine

Featured Publications

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).

Mahadevan D, Theiss N, Morales C, Stejskal AE, Cooke LS, Zhu M, Kurtzman D, Swart R, Ong E, Qi W, Oncotarget 2015 Feb 6 4 1954-66

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Durden DL, Ramanathan RK, Eur. J. Cancer 2012 Dec 48 18 3319-27

Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W, Clin. Cancer Res. 2012 Apr 18 8 2210-9

Radioprotection from radiation-induced lymphedema without tumor protection.

Daley SK, Bernas MJ, Stea BD, Bracamonte F, McKenna M, Stejskal A, Hirleman ED, Witte MH, Lymphology 2010 Jun 43 2 48-58

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.

Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D, BMC Cancer 2009 May 9 142

NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells.

Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D, Oncogene 2008 Jul 27 30 4210-20

• Silver Pin Award
  Osteopathic Community Health Volunteer Award (2013)
• Sigma Sigma Phi - Rho Chapter
  Osteopathic National Honor and Service Fraternity (2012)